A comprehensive analysis of the molecular characteristics of gliomas—the most common malignant brain tumor—explains why some patients diagnosed with slow-growing (low-grade) tumors quickly succumb to the disease while others with more aggressive (high-grade) tumors survive for many years.
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.
Scientists at Columbia University’s Mortimer B. Zuckerman Mind Brain Behavior Institute have developed a new viral tool that dramatically expands scientists’ ability to probe the activity and circuitry of brain cells, or neurons, in the mouse brain.
Columbia Engineering researchers have shown, for the first time, that electrical stimulation of human heart muscle cells (cardiomyocytes) engineered from human stem cells aids their development and function.
The targeted cancer drug ibrutinib has recently transformed the treatment of chronic lymphocytic leukemia, adding years to the lives of patients with hard-to-treat disease who were told they had just months to live.
The Defense Advanced Research Projects Agency (DARPA) has established a new Electrical Prescriptions (ElectRx) program to help spur research in this area, with the goal to develop new technologies that could improve physical and mental health by using targeted stimulation of the peripheral nervous system to exploit the body’s natural ability to quickly and effectively heal itself.